Glycemic control [using HbA1c (%) levels] after three months of treatment with repaglinide versus metformin monotherapy; as initial treatment in patients with newly diagnosed type 2 diabetes mellitus naive to oral hypoglycemic agents

Comparison of Metformin versus Repaglinide monotherapy in the treatment of new-onset type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2025/014

Enrollment

Unknown

Registered

2025-04-09

Start date

2025-04-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Study setting: Department of Medicine, Nishtar Hospital Multan, Pakistan. Randomization: Lottery method using sealed opaque envelopes. Intervention: (A) Active / Experimental: Repaglinide monotherap

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients 20 – 60 years of age. 2. Both male or female gender. 3. Newly diagnosed T2DM as per World Health Organization criteria.

Exclusion criteria

Exclusion criteria: 1.Existing coronary artery disease 2. Renal disease 3. Liver disease 4. Gastrointestinal diseases assessed on history and medical record review.

Design outcomes

Primary

Measure	Time frame
Outcome: Glycemic control Metric: HbA1c (%) Method of Measurement: Measured by high pressure liquid chromatography [Three months after treatment assignment]	—

Secondary

Measure	Time frame
None [None]	—

Countries

Pakistan

Contacts

Public ContactWaseem Ahmad

Postgraduate Resident

waseemghani302@gmail.com061-9200993, 061-9200231

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 10, 2026